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Background: RNA quantification is often a prerequisite for most RNA analyses such as RNA sequencing. However,
the relatively low sensitivity and large sample consumption of traditional RNA quantification methods such as UV
spectrophotometry and even the much more sensitive fluorescence-based RNA quantification assays, such as the
Qubit™ RNA HS Assay, are often inadequate for measuring minute levels of RNA isolated from limited cell and tissue
samples and biofluids. Thus, there is a pressing need for a more sensitive method to reliably and robustly detect
trace levels of RNA without interference from DNA.
Methods: To improve the quantification limit of the Qubit™ RNA HS Assay, we spiked-in a known quantity of RNA
to achieve the minimum reading required by the assay. Samples containing trace amounts of RNA were then added to
the spike-in and measured as a reading increase over RNA spike-in baseline. We determined the accuracy and precision
of reading increases between 1 and 20 pg/μL as well as RNA-specificity in this range, and compared to those of
RiboGreen®, another sensitive fluorescence-based RNA quantification assay. We then applied Qubit™ Assay with
RNA spike-in to quantify plasma RNA samples.
Results: RNA spike-in improved the quantification limit of the Qubit™ RNA HS Assay 5-fold, from 25 pg/μL down
to 5 pg/μL while maintaining high specificity to RNA. This enabled quantification of RNA with original concentration as
low as 55.6 pg/μL compared to 250 pg/μL for the standard assay and decreased sample consumption from 5 to
1 ng. Plasma RNA samples that were not measurable by the Qubit™ RNA HS Assay were measurable by our modified
method.
Conclusions: The Qubit™ RNA HS Assay with RNA spike-in is able to quantify RNA with high specificity at 5-fold
lower concentration and uses 5-fold less sample quantity than the standard Qubit™ Assay.
Keywords: Lower quantification limit, Minimum RNA concentration, Plasma RNA, Qubit™ RNA HS Assay,
RNA quantification, RNA spike-inBackground
Recent studies utilizing trace amounts of RNA present
in biospecimens such as biofluids, single cells and
minute clinical samples have revealed their novel func-
tions and biomedical potentials [1-14]. RNA quantifica-
tion is an important and necessary step prior to most
RNA analyses. However, it can be very challenging
to quantify RNA present in the pg/μL ranges found in
biofluids and minute cell and tissue samples [6]. After* Correspondence: zev.williams@einstein.yu.edu
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stated.purification using most commercial RNA isolation kits,
the concentrations of purified plasma RNA samples are
often less than 200 pg/μL. UV spectrophotometry com-
monly used for nucleic acid quantification has a lower
quantification limit around 4 ng/μL, and is therefore not
suitable for measuring RNA samples with such low
concentrations [15-17].
An alternative approach is fluorescence-based RNA
quantification that utilizes the fluorescent property of
nucleic acid binding dyes. Unbound dyes are nearly
non-fluorescent, but upon binding to nucleic acid,
the complex exhibits a large increase in fluorescence,
thereby greatly amplifying nucleic acid signal for detec-
tion at concentrations much lower than that requiredis an Open Access article distributed under the terms of the Creative Commons
/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
roperly credited. The Creative Commons Public Domain Dedication waiver
zero/1.0/) applies to the data made available in this article, unless otherwise
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of fluorescence-based RNA quantification methods is
the Qubit™ RNA HS Assay (Life Technologies, Thermo
Fisher Scientific Inc.).
The Qubit™ RNA HS Assay is highly selective for RNA
over DNA [22] and provides a minimum “reading” (RNA
concentration in the Qubit™ working solution) of 25 pg/μL
with high confidence (deviation from ideal < 20%). Up to
20 μL of RNA sample can be added in a 200 μL Qubit™
Assay, and therefore RNA samples with a minimum
starting concentration of 250 pg/μL can be accurately
quantified. However, this minimum concentration is
still relatively high compared to levels of RNA found in
certain biological specimens. Moreover, the assay con-
sumes a minimum of 5 ng of RNA sample, which may
leave insufficient RNA for downstream applications.
Thus, these detection limitations to the Qubit™ Assay
can hinder the analysis and application of some bio-
logical samples with extremely low RNA quantities.
Here we used an RNA spike-in to set a baseline read-
ing of the Qubit™ Assay and measured RNA sample as
an increase over RNA spike-in. This method was vali-
dated to accurately measure RNA at lower concentra-
tions and require less sample compared to standard
Qubit™. We tested the utility of this spike-in approach
by measuring plasma RNA samples that fell below the
detection limit of the standard Qubit™ Assay. We named
the modified assay the Spike-in Qubit™ RNA HS Assay
because this optimization takes advantage of an RNA
spike-in.
Methods
Validation of the Spike-in Qubit™ RNA HS assay
The Qubit™ RNA HS Assay Kit (Life Technologies,
Thermo Fisher Scientific Inc.), Qubit™ 2.0 Fluorometer
(Life Technologies, Thermo Fisher Scientific Inc.) and
Axygen PCR-05-C tubes (Axygen) were used for all
measurements. The Qubit™ working solution was made
according to manufacturer’s instructions. We added
180 μL of working solution to each assay tube, up to
20 μL of RNA, and water to bring the final volume to
200 μL. 10 μL of the Qubit™ RNA Standard solutions
were used for standard tubes. “RNA spike-in” was made
by diluting the Qubit™ RNA Standard #2 (10 ng/μL
rRNA) included in the Qubit™ RNA HS Assay kit to
2.5 ng/μL and 2 μL was added into each tube. 18 μL of
water was added into one tube for RNA spike-in alone
reading. “RNA sample” was made by diluting the Qubit™
RNA Standard #2 to 250 pg/μL and increasing volumes
of RNA sample were added into remaining tubes to
create expected reading increases of 1, 2, 3, 4, 5, 7.5, 15
and 20 pg/μL over RNA spike-in alone. Assay tubes
were vortexed for 2–3 s, centrifuged briefly (~5 s), and
then incubated at room temperature for 2 min to allowthe assay to reach optimal fluorescence before measur-
ing with the Qubit™ Fluorometer. Each tube was mea-
sured three times to obtain the average reading. Reading
increase was calculated by subtracting RNA spike-in
reading from that of spike-in plus sample RNA reading.
The experiment was repeated four times using inde-
pendently prepared RNA spike-in, RNA sample, and
working solution. In addition, the total RNA from
human trophoblast cells was used as “RNA sample” and
tested as described above for a total of four independent
experiments.
Comparison between the Spike-in Qubit™ RNA HS Assay
and Quant-iT™ RiboGreen® RNA Assay
Based on the original concentration measured by
NanoDrop® ND-1000 (Thermo Fisher Scientific Inc.),
the trophoblast total RNA was diluted to 60 pg/μL in
water. A mixture of RNA and DNA (60 pg/μL each)
was prepared by diluting in water the trophoblast total
RNA and the Qubit™ DNA Standard #2 (10 ng/μL
DNA) included in the Qubit™ DNA HS Assay kit. 18 μL
of each sample was measured by the Spike-in Qubit™ as
described above and by the Quant-iT™ RiboGreen®
RNA Assay (Life Technologies, Thermo Fisher Scien-
tific Inc.) following manufacturer’s instructions using a
BioTek Synergy™ 4 Multi-Mode Microplate Reader
(BioTek). Four independent repeats were performed
with each method.
Quantification of plasma RNA samples
The standard Qubit™ RNA HS Assay was performed
according to manufacturer’s instructions. The Spike-in
Qubit™ RNA HS Assay was performed as described
above. For the Spike-in Qubit™ Assay, RNA sample con-
centration was calculated as: [Sample] = reading increase
(pg/μL) x assay volume (μL) ÷ sample volume for Spike-
in Qubit™ (μL). Three independent measurements using
separately prepared RNA spike-in and Qubit™ reagents
were made for each sample. A detailed step-by-step
protocol for the Spike-in Qubit™ RNA HS Assay is pro-
vided in the Supplementary Methods.
Sample preparation and RNA isolation
After obtaining informed consent, 8.5 mL of peripheral
blood samples were collected into Vacutainer™ tubes
containing acid citrate dextrose solution A (BD) and im-
mediately inverted eight times to mix anticoagulant
additive with blood. Blood samples were centrifuged at
1,900 g for 10 min at 4°C in a swinging-bucket centri-
fuge (Eppendorf ) and plasma was aspirated using dis-
posable transfer pipets (VWR), aliquoted into 2 mL
polypropylene microcentrifuge tubes (Sarstedt) and
centrifuged at 16,050 g for 5 min at 4°C in a benchtop
centrifuge (Eppendorf ). The final plasma was pooled
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1.5 mL DNA LoBind tubes (Eppendorf ), snap frozen in
liquid nitrogen and stored at −80°C. Plasma RNA isolation
was performed using three commercial RNA isolation kits:
miRCURY™ RNA Isolation Kit – Biofluids (Exiqon),
mirVana™ PARIS™ Kit (Life Technologies, Thermo Fisher
Scientific Inc.) and miRNeasy Micro Kit (Qiagen) fol-
lowing manufacturer recommended protocols. The
miRCURY™ kit is designed to isolate RNA shorter than
1000 nucleotides (nt) and the mirVana™ and miRNeasy
kits isolate total RNA.
After informed consent was obtained, tissues were
collected from manual vacuum aspiration. To isolate
trophoblast cells, chorionic villi were identified and
floated in DPBS supplemented with 10 mg/ml Gentamy-
cin, minced with sterile scalpel blades, placed in 35 ×10
mm dishes and incubated with 3.3 mg/ml Collagenase
(Sigma) for about 2 hours at 37°C in the cell incubator.
Cells were further washed twice with Amniomax complete
medium (Amionax basal medium plus F100 supplement;
GIBCO) and cultured in Amniomax complete medium
for 7 days. RNA from trophoblast cells was extracted with
All Prep® DNA/RNA/Protein mini kit (Qiagen) according
to the manufacturer’s protocol. All aspects of these studies
were reviewed and approved by the Institutional Review
Board at Albert Einstein College of Medicine.
Data analyses
Data analyses were performed using Excel® for Mac 2011
(Microsoft) and GraphPad Prism 6 (GraphPad Software).
Relative error (RE) was calculated as RE = (average mea-
sured reading − expected reading) ÷ expected reading.Figure 1 Schematic diagram of the Spike-in Qubit™ RNA HS Assay. RNA sp
Qubit™. Then nuclease-free water or RNA sample (orange) was added for Q
for RNA spike-in plus RNA sample. The reading for RNA sample is (R2 - R1)
(pg/μL) × assay volume (μL) ÷ sample volume for the assay (μL).Coefficient of variation (CV) was calculated as CV =
standard deviation ÷ average measured reading. Deviation
from ideal was calculated as the sum of the absolute value
of RE and CV. A two-way ANOVA interaction analysis
was performed to determine whether the differences be-
tween the measurements of the 60 pg/μL RNA sample
and those of the mixed RNA and DNA sample (60 pg/μL
each) were consistent for the Spike-in Qubit™ RNA HS
Assay and the Quant-iT™ RiboGreen® RNA Assay.
Results and discussion
The lower reading limit of the Qubit™ RNA HS assay for
accurate quantification is 25 pg/μL (deviation from
ideal < 20%). In order to quantify samples that fall below
this limit, prior to adding the RNA sample that was to
be measured, we added 5 ng of RNA spike-in (2.5 ng/μL
Qubit™ RNA standard #2) into a 200 μL Qubit™ assay to
generate an expected baseline reading of 25 pg/μL.
Then, the RNA sample was added to the baseline and
the increase over baseline would correspond to the
reading of RNA sample (Figure 1).
To evaluate the ability of our Spike-in Qubit™ Assay
to measure increases in the range of 1 to 20 pg/μL, an
RNA sample (250 pg/μL Qubit™ RNA standard #2) was
added at increasing volumes into Qubit™ assay tubes
containing RNA spike-in to create expected reading
increases ranging from 1 to 20 pg/μL. As shown in
Figure 2A, the Spike-in Qubit™ Assay achieved optimal
linear regression with slope of 1.0324, and R2 of 0.99837
after four independent experiments (Additional file 2:
Table S1). To represent a typical RNA sample that
might introduce additional influences on fluorometricike-in (green) was added to reach the lower quantification limit of
ubit™ measurement. R1 is the reading for RNA spike-in alone and R2
and RNA sample concentration is calculated as [sample] = (R2 – R1)
Figure 2 Reading increases between 1 and 20 pg/μL show a strong
linear correlation in the Spike-in Qubit™ RNA Assay. RNA spike-in
alone or with increasing amounts of a 250 pg/μL Qubit™ RNA Standard
#2 sample (A) or a 250 pg/μL trophoblast total RNA sample (B) was
measured by the Qubit™ Assay. Reading increases over RNA spike-in
were plotted against expected reading increases. Regression line
equation, coefficient of determination (R2) and error bars indicating
standard deviation are shown. N = 4 independent repeats.
Table 1 The Spike-in Qubit™ RNA HS Assay achieves














1 1.1 ± 1.3 12.5% 114.6% 127.1%
2 2.7 ± 0.7 32.5% 27.6% 60.1%
3 3.2 ± 0.4 7.5% 13.6% 21.1%
4 4.1 ± 0.8 2.5% 19.9% 22.4%
5 5.3 ± 0.2 6.3% 4.6% 10.9%
7.5 7.8 ± 0.5 3.6% 5.8% 9.4%
10 10.7 ± 0.5 6.9% 4.7% 11.6%
15 15.5 ± 0.3 3.4% 1.7% 5.1%
20 20.3 ± 0.9 1.6% 4.4% 6.0%
A 250 pg/μL Qubit™ RNA Standard #2 RNA sample was used to assess the
accuracy and precision of reading increases between 1 and 20 pg/μL using
the Spike-in Qubit™. Average measured reading increase ± standard deviation
(SD), relative error, coefficient of variation, and deviation from ideal expressed
in percent are listed in the table. N = 4 independent repeats.
Table 2 The Spike-in Qubit™ RNA HS Assay achieves













1 1.7 ± 0.8 65.8% 50.6% 116.5%
2 2.9 ± 0.7 44.2% 23.9% 68.0%
3 3.0 ± 0.5 0.6% 16.7% 17.3%
4 4.4 ± 0.8 10.6% 18.4% 29.1%
5 5.1 ± 0.8 2.2% 16.3% 18.5%
7.5 7.2 ± 0.7 −4.1% 9.6% 13.7%
10 9.7 ± 1.0 −2.6% 10.5% 13.0%
15 14.5 ± 0.8 −3.6% 5.2% 8.8%
20 19.3 ± 1.0 −3.7% 5.3% 9.0%
A 250 pg/μL trophoblast total RNA sample was used to assess the accuracy
and precision of reading increases between 1 and 20 pg/μL using the Spike-in
Qubit™. Average measured reading increase ± standard deviation (SD), relative
error, coefficient of variation, and deviation from ideal expressed in percent
are listed in the table. N = 4 independent repeats.
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250 pg/μL human trophoblast total RNA sample. Strong
linear correlation was also evident with slope of 0.9723
and R2 of 0.99469 (Figure 2B) after four independent
experiments (Additional file 2: Table S2).We assessed the accuracy and precision of the Spike-
in Qubit™ Assay for all tested reading increases in order
to determine the lower quantification limit that passed
accuracy and precision requirements. Accuracy is in-
versely correlated to the relative error (RE) and preci-
sion is inversely correlated to the coefficient of variation
(CV). The Qubit™ RNA HS Assay used “deviation from
ideal”, the combined value of the absolute value of RE
and CV, to evaluate the precision and accuracy and set
deviation from ideal of <20% for its lower quantification
limit in the core quantification range. Using the same
criterion, we determined that Spike-in Qubit™ Assay
achieved a lower quantification limit of 5 pg/μL for both
Table 3 The spike-in Qubit™ RNA HS Assay reduces
minimal RNA concentration and sample consumption
QubitTM Spike-in QubitTM
Lower Quantification Limit (pg/μL) 25 5
Max. Sample Volume (μL) 20 18*
Min. Sample Concentration (pg/μL) 250 55.6
Min. Sample Quantity (ng) 5 1
The lower quantification limit and maximum sample volume for the Qubit™
Assay and Spike-in Qubit™ Assay and their corresponding minimal sample
concentration and quantity are listed in the table. *2 μL RNA Spike-in is added
into each assay tube, leaving maximally 18 μL for RNA sample in a 200 μL assay.
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which is 80% less than that of the standard Qubit™
Assay (25 pg/μL) (Tables 1 and 2). This new lower
quantification limit allowed quantification of RNA sam-
ples with original concentrations as low as 55.6 pg/μL
and reduced minimal sample consumption from 5 ng to
1 ng (Table 3).
We also cross-compared the precision and accuracy of
the Spike-in Qubit™ Assay with those of the Quant-iT™
RiboGreen® RNA Assay that has a lower quantification
limit of 1 pg/μL. A 60 pg/μL trophoblast total RNA sam-
ple was measured in four independent repeats with both
methods (Additional file 2: Table S3 and S4). As shown
in Table 4, the RNA concentration measured by the
Spike-in Qubit™ was 63.6 ± 3.4 pg/μL and 53.4 ± 1.3 pg/μL
by the Quant-iT™. Both methods achieved good preci-
sion with CVs of 5.4% and 2.5% for the Spike-in Qubit™
and the Quant-iT™, respectively. In contrast to the
Quant-iT™ RiboGreen® RNA Assay and most other
methods including UV spectrometer, the Qubit™ RNA
Assay is reported to be selective to RNA over DNA
[15,16,18,22]. DNA at 8 times higher concentration of
the lower quantification limit (25 pg/μL) is not detect-
able in the Qubit™ RNA Assay and an equal mixture of
DNA and RNA up to 200 pg/μL each in the assay does
not affect the reading of RNA [22]. To test if the Spike-
in Qubit™ maintains RNA specificity at low readings, weTable 4 The Spike-in Qubit™ RNA HS Assay maintains











60 pg/μL RNA 5.7 ± 0.3 63.6 ± 3.4 4.8 ± 0.1 53.4 ± 1.3
60 pg/μL RNA +
60 pg/μL DNA
5.8 ± 0.6 64.2 ± 6.2 17.1 ± 0.6 190.1 ± 6.1
A 60 pg/μL RNA sample and a mixture of 60 pg/μL RNA and 60 pg/μL DNA
were measured by the Spike-in Qubit™ and the Quant-iT™ RiboGreen® Assays.
Average reading ± standard deviation (SD) and corresponding RNA concentration
± SD are listed in the table. N = 4 independent repeats.mixed the 60 pg/μL RNA with 60 pg/μL DNA. The
reading for the mixture was 64.2 ± 6.2 pg/μL, similar to
the 60 pg/μL RNA concentration measured by the
Spike-in Qubit™. In contrast, the presence of DNA
significantly increased the quantification value by the
Quant-iT™ from 53.4 ± 1.3 pg/μL for the RNA sample to
190.1 ± 6.1 pg/μL for the RNA plus DNA sample. A
two-way ANOVA analysis determined that the differ-
ences in the measurements of the RNA sample and those
of the mixed RNA and DNA sample were significantly
different between the Spike-in Qubit™ RNA HS Assay and
the Quant-iT™ RiboGreen® RNA Assay (P < 0.0001).
RNA samples purified from serum or plasma are present
at low concentration (~30 ng per 1 mL of plasma), making
their quantification challenging [6,23,24]. To determine
whether our newly validated Spike-in Qubit™ Assay would
enable accurate measurements from these samples which
would normally be at too low of a concentration to be
measured with standard Qubit™, we used both assays to
measure plasma RNA samples purified using three com-
mercial RNA isolation kits. All three samples fell below
the detection limit of the standard Qubit™ and therefore
their concentrations could not be determined (Table 5). In
contrast, The Spike-in Qubit™ Assay achieved quantifica-
tion for all samples while consuming 25-50% less samples
than the standard Qubit™ (Table 5).
We speculate that the Spike-in Qubit™ approach may
work because the readings of RNA spike-in alone and
with additional RNA samples fall into the linear and
high-precision quantification range of the Qubit™. It
ensures that the reading increase over RNA spike-in
baseline is of high precision and linear therefore of high
accuracy. There are limitations to the Spike-in Qubit™
RNA HS Assay. First, it requires extra steps to prepare
and add RNA spike-in. However, these steps only consist
of diluting the Qubit™ RNA Standard #2 (that comes
pre-made in the kit) and adding it into a master mix.
Therefore, the time and risk of introducing error are
minimal. In addition, because an excess amount of
Qubit™ RNA Standard #2 is provided in the Qubit™
Assay kit, there is no need to purchase additional re-
agents. As the validation for reading increases between 1
and 5 pg/μL was performed by adding RNA samples in
0.8 to 4 μL volumes, Pipetting of small volumes could
have contributed to variation in measurements due to
pipetting error.
Conclusions
The Spike-in Qubit™ RNA HS Assay reported here
achieved accurate and precise RNA quantification at a
new lower quantification limit of 5 pg/μL, 5-fold lower
than that of the standard Qubit™, while maintaining the
RNA specificity of the original assay. This improvement
lowers minimal RNA concentration measurable from















1 20 <20 N.D. 10 5.3 ± 0.7 106.0 ± 14.0 13.2%
2 20 < 20 N.D. 15 13.2 ± 1.8 176.4 ± 23.4 13.3%
3 20 < 20 N.D. 15 6.0 ± 0.3 80.0 ± 3.5 4.4%
Plasma RNA samples purified using the three kits listed in the Methods were quantified by the Qubit™ and the Spike-in Qubit™ Assays. Sample volume used for
quantification, Qubit™ reading or Spike-in Qubit™ reading increase ± standard deviation (SD) and corresponding RNA concentration ± SD and coefficient of variation
(CV) are listed in the table. “ < 20” indicates the reading is below the Qubit™ detection limit and therefore sample RNA concentration could not be determined (N.D.) For
the Spike-in Qubit™, RNA sample concentration was calculated as described in the Methods. N = 3 independent repeats.
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sumption from 5 ng to 1 ng. As demonstrated in the
successful quantification of plasma RNA samples, the
Spike-in Qubit™ RNA HS can be readily used to quantify
RNA samples having low concentrations and limited
quantities.
Additional files
Additional file 1: The Spike-in Qubit™ RNA HS Assay Protocol.
Additional file 2: Table S1. Four independent Spike-in Qubit™
measurements of reading increases between 1 and 20 pg/μL using a 250
pg/μL Qubit™ Standard #2 RNA sample. Table S2. Four independent
Spike-in Qubit™ measurements of reading increases between 1 and 20
pg/μL using a 250 pg/μL trophoblast total RNA sample. Table S3. Four
independent Spike-in Qubit™ measurements of a 60 pg/μL trophoblast
total RNA sample or a mixure of trophoblast total RNA and Qubit™ Standard
#2 DNA (60 pg/μL each). Table S4. Four independent Quant-iT™ RiboGreen®
measurements of a 60 pg/μL trophoblast total RNA sample or a mixure
of trophoblast total RNA and Qubit™ Standard #2 DNA (60 pg/μL each).
Table S5. Three independent Spike-in Qubit™ measurements of plasma
RNA samples.
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